Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa
A line of biopharmaceutical products on a laboratory shelf waiting to be tested.
The feedback stems from encouraging data from the TACTI-003 Phase 2b trial evaluating efti with MSD's anti-PD-1 KEYTRUDA (pembrolizumab). Immutep Limited (NASDAQ:IMMP) said that the FDA acknowledged the potential of the combination to address the high unmet need in patients with CPS <1 and supports its further development.
Marc Voigt, CEO of Immutep Limited (NASDAQ:IMMP), shared the following remarks on the development:
'We are pleased with the FDA's feedback and guidance that underscores the high unmet need of head and neck cancer patients whose PD-L1 expression level is below one. The FDA feedback positions Immutep to evaluate options for future collaborative clinical development paths to bring a new, effective and safe treatment option to this underserved patient population.'
Looking ahead, Immutep Limited (NASDAQ:IMMP) also outlined paths for future clinical development. This would include a randomised registrational trial evaluating the combination against standard-of-care therapy, or lead a smaller single-arm study on about 70-90 patients, followed by a confirmatory randomised study building on the existing findings.
While we acknowledge the potential of IMMP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 minutes ago
- Bloomberg
Trade Partners Grow Restless Waiting for Trump's Tariff Breaks
UK Prime Minister Keir Starmer declared at a Jaguar Land Rover factory in May that his world-leading trade deal with President Donald Trump included a cut in US tariffs on British steel to zero. More than three months later, steel lobbyist Peter Brennan was still waiting for that relief to become reality.
Business Insider
24 minutes ago
- Business Insider
The Week That Was, The Week Ahead: Macro & Markets, August 17, 2025
Everything to Know about Macro and Markets Stocks ended the week on a soft note, still managing to lock in back-to-back weekly gains. The S&P 500 (SPX) rose 0.94% for the week, and the Nasdaq-100 (NDX) inched up 0.43%. The Dow Jones Industrial Average (DJIA) was the standout, delivering a weekly gain of 1.74%. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. A Week of Contrasts After a red Monday, all three major indexes reached all-time highs on Tuesday. This followed in-line CPI data, which bolstered bets that the Fed would deliver its first rate cut of 2025 in September – traders have priced in nearly a 100% chance of a 25-bps easing. Stocks extended gains on Wednesday: the S&P 500 and Nasdaq hit new ATHs again amid remarks from Treasury Secretary Scott Bessent urging a 50-bps cut based on downward revisions in payroll data. Wall Street analysts began forecasting up to three cuts this year, citing a softer labor market, limited tariff pass-through to consumer prices, and the appointment of Trump's temporary Fed board pick. But those forecasts were questioned Thursday when PPI, which tracks wholesale price trends, came in hotter than expected, denting sentiment and clouding the Fed outlook. Other economic reports pulled markets in opposing directions: July's industrial production was lackluster – although not recession-bellwether weak – while retail sales beat forecasts, underscoring resilient consumer demand despite high borrowing costs. Meanwhile, the UoM consumer sentiment unexpectedly slipped and inflation expectations rose, muddying the outlook for Fed cuts in September. On Friday, the Dow's gains were dominated by UnitedHealth's surge following Berkshire Hathaway's disclosure of a large stake in the embattled healthcare giant. Meanwhile, the S&P 500 and Nasdaq's advances were tempered by tech weakness amid cautious corporate outlooks and persistent tariff concerns, particularly in semiconductors. This week featured leadership rotation: healthcare and small-caps rose, while semiconductors and tech lagged under the weight of inflation and trade worries. With mixed inflation and consumer data re-injecting uncertainty into the Fed policy outlook, all eyes now turn to Jackson Hole. Jerome Powell's speech on August 22 is the marquee event, expected to instantly influence markets. A dovish tone could broaden the rally, boosting small caps, rate-sensitive areas, and tech. A hawkish stance – highlighting inflation risks or caution – could trigger sharp corrections and volatility, especially in growth and rate-sensitive sectors. Adaptability, Profitability, and Capex Economic data remains mixed – but corporate signals are broadly bullish, despite overbought pockets and uneven strength. As Benjamin Graham famously said, 'in the short run, the market is a voting machine but in the long run, it is a weighing machine.' Prices may swing on sentiment or episodic events, but over time, earnings growth is what ultimately matters. On that front, Q2 2025 earnings have been compelling: over 90% of companies have reported, with average EPS growth near 11% year-over-year – versus expectations of 3-4% at the quarter's start. This follows a similar pattern seen in Q1 season. In the second quarter, 84% beat expectations, surprising by an average of 9%. U.S. companies' adaptability – particularly in counteracting tariff shocks – is helping shield both the economy and equity markets. Notably, S&P 500 forward 12-month EPS estimates are now at record highs, driven largely by tech megacap profitability and reinvestment. AI capex alone has contributed more to GDP growth in H1 2025 than consumer spending. While over the long term, consumer demand has been the undisputed engine of growth – megacaps' AI and cloud investment plans signal continued acceleration of their role in fueling the expansion. The sterling Q2 earning-growth results have broadly dispelled investor fears over trade policies weighing on the economy and corporate performance. FactSet reports that 'recession' mentions in earnings calls dropped nearly 70% from Q1 2025, hitting their lowest levels since 2005. Polymarket's 2025 recession odds plunged from over 65% in May to 12%, signaling there's no longer a belief that levies on imports mean a recession is imminent. Tariffs still get airtime, even if much less than in Q1 – but the C-suite and market participants now see them as manageable. Factors such as lower energy prices and decelerating housing-related inflation are further diluting the tariff impact. Strategists now expect any tariff impact on inflation to be delayed and muted, with economic growth holding relatively firm. Stocks That Made the News ▣ UnitedHealth (UNH) soared over 22% on the week after Berkshire Hathaway ($BRK.B) disclosed a new stake in the beaten-down healthcare provider. Warren Buffett's conglomerate acquired 5.04 million UNH shares valued at $1.57 billion. ▣ Applied Materials (AMAT) plunged 13% despite delivering record performance last quarter, as the chip equipment provider offered weaker-than-expected guidance amid weak China demand, stalled export license approvals, and uneven orders. Despite the near-term challenges, the company remains optimistic about mid-single-digit growth for fiscal 2025, driven by investments in U.S. manufacturing and advancements in semiconductor technology. ▣ Intel (INTC) was on the winning side of the semi trade, popping by over 22% on the week following reports that the Trump administration was mulling the potential for the government to take a stake in the embattled company to aid domestic chip manufacturing expansion. ▣ Palantir Technologies (PLTR) declined after Andrew Left, head of short-selling firm Citron Research, said he was betting against the company in light of its lofty valuation, which he called 'absurd.' ▣ Amazon (AMZN) rallied as analysts applauded analysts applauding its expansion into free same-day grocery delivery nationwide for Prime members. Evercore ISI said that this expansion deepens Amazon's customer engagement by strengthening a high-frequency purchase category into the Prime ecosystem, increasing stickiness and customer lifetime value. ▣ Oracle (ORCL) also bucked the down trend on Friday, rallying on news of expanded partnership with Alphabet's (GOOGL) Google Cloud. Under the collaboration, Oracle will integrate Google's Gemini AI models into Oracle Cloud Infrastructure (OCI). This allows Oracle's enterprise customers to access Google's Gemini AI capabilities – including multimodal understanding, coding assistance, and workflow automation – via OCI services, enhancing productivity and workflow automation. The deal – similar to one that Oracle struck with Elon Musk's xAI back in June – is expected to significantly broaden Oracle's AI offerings, advancing its strategy of offering a menu of AI options rather than trying to push its own technology exclusively. The Q2 2025 earnings season is winding down, but several notable releases are still scheduled for this week. These include: Palo Alto Networks (PANW), Home Depot (HD), Medtronic (MDT), Keysight Technologies (KEYS), TJX Companies (TJX), Lowe's (LOW), Analog Devices (ADI), Target (TGT), Walmart (WMT), Intuit (INTU), Workday (WDAY), and Ross Stores (ROST).
Yahoo
30 minutes ago
- Yahoo
Thinking of Buying Tesla Stock? Here Are 2 Red Flags to Watch
Key Points Tesla's heavy reliance on Elon Musk adds significant leadership risk. Increasing competition from established automakers and Chinese EV makers is pressuring Tesla's dominance. Investors need to be comfortable with Tesla's high valuation. These 10 stocks could mint the next wave of millionaires › Tesla (NASDAQ: TSLA) has long been the front runner in the electric vehicle (EV) revolution in the U.S. Its innovation, brand strength, and rapid growth have made it a favorite among investors. Yet, despite its impressive track record, there are two big risks that investors should carefully consider before buying Tesla stock today. 1. The Elon Musk factor Elon Musk's leadership is often cited as Tesla's greatest strength -- and, paradoxically, one of its most significant vulnerabilities. Musk's vision and hands-on approach have driven Tesla's technological breakthroughs and ambitious expansion. However, this heavy reliance on a single individual introduces what investors refer to as "key man risk." If Musk were to step back from daily operations or shift his focus to other projects, Tesla might face challenges in maintaining its momentum. Though Tesla's management team has grown stronger, few executives command the same vision, drive, and public attention as Musk. Recently, Musk's increasing involvement in political activities has raised concerns about potential distractions or reputational risks for Tesla. While the company has remained operationally strong, these developments underscore the uncertainty around its future leadership continuity. While Tesla's success lies not only with Musk but also with his team, which has executed well on his vision -- no one can build a trillion-dollar company alone -- there is still no clear successor (or a viable management team) . The silver lining here is that the Tesla board has become more serious about finding one in recent months, largely due to the CEO's active involvement in politics. For investors, this means that Tesla's fortunes remain closely tied to Musk's presence and decisions -- a factor that adds a layer of risk to the investment. 2. Intensifying competition Tesla might have been an early mover in the EV industry, but its dominance is no longer guaranteed. The industry landscape is rapidly evolving, with legacy automakers and new entrants accelerating their electric ambitions. Companies like Ford and General Motors are aggressively expanding their EV lineups. For instance, Ford plans to introduce a $30,000 midsize truck by 2027. That price is significantly lower than the average for an EV, and Ford is investing $5 billion in its EV production to make it happen. GM, on the other hand, is working hard on next-generation battery technologies to improve range, charging performance, and cost. Meanwhile, Chinese manufacturers such as BYD are growing their international footprints, particularly in Europe, where Tesla experienced a nearly 27% sales declinein July 2025. BYD's battery technology, government support, and competitive pricing make it a formidable challenger. In addition, a host of EV start-ups are innovating in battery tech, autonomous driving, and new business models, further intensifying competition. While Tesla is not sitting still -- it is working on becoming the lowest-cost producer by cutting prices to grow sales volume and achieve economies of scale -- there is no guarantee that it can maintain its market share over time. In short, it's no longer the only player in town. What does this mean for investors? Tesla's story remains compelling: It's a pioneer with a powerful brand, innovative products, and potential optionality with some of its long shot bets (robotaxi, humanoid robots, etc). But the key man risk surrounding Musk and the escalating competitive landscape are real concerns that investors can't ignore. If Tesla continues to innovate more rapidly than its rivals, the company could sustain its growth trajectory. However, any leadership changes or slips in market position could hurt the business and its share price. While these two risks don't necessarily call for the sale of the stock, they do mean that investors should think carefully before buying the stock today. Tesla stock trades at a significant premium valuation to other carmakers. For perspective, Tesla has a price-to-sales (P/S) ratio of 12.9, compared to GM's 0.3. Unless you're comfortable with the risks and the high valuation, buying the stock today may not be a prudent decision. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $467,985!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $44,015!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $668,155!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 13, 2025 Lawrence Nga has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool recommends BYD Company and General Motors. The Motley Fool has a disclosure policy. Thinking of Buying Tesla Stock? Here Are 2 Red Flags to Watch was originally published by The Motley Fool
